vTv Therapeutics (VTVT) Revenue (2014 - 2026)

vTv Therapeutics (VTVT) posted Revenue of $36.8 million for Q1 2026, up 216600.0% sequentially from $17000.0 in Q4 2024.

vTv Therapeutics (VTVT) Revenue (2014 - 2026) Analysis & Trends

vTv Therapeutics has reported Revenue for 11 years, with the latest figure at $36.8 million in Q1 2026.

Quarterly Revenue changed N/A year-over-year to $36.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.8 million (up 216600.0% YoY) and the FY2024 annual result came in at $1.0 million, changed N/A from the prior year.
Revenue grew to $36.8 million in Q1 2026 per VTVT's latest filing, from $17000.0 in the prior quarter.
Over five years, Revenue peaked at $36.8 million in Q1 2026 and troughed at $9000.0 in Q2 2022.
A 3-year average of $6.6 million and a median of $508500.0 in 2024 frame the typical range for Revenue.
The widest YoY moves for Revenue: up 102.63% in 2022, down 0.0% in 2022.
Over 3 years, Revenue stood at $9000.0 in 2022, then soared by 88.89% to $17000.0 in 2024, then soared by 216600.0% to $36.8 million in 2026.
According to Business Quant data, Revenue over the past three periods registered $36.8 million, $17000.0, and $1.0 million for Q1 2026, Q4 2024, and Q1 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.56 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.71 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3,001.92
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	674.14 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.29 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	425.49 Mn
10	vTv Therapeutics	373.77 Mn	373.77 Mn	-	-

Download Data